Background. The Extracorporeal Life Support Organization (ELSO) Infectious
Disease Taskforce has identified infection rates as an area requiring further study. We aimed to evaluate our patients on venous-venous extracorporeal membrane oxygenation (VV ECMO) for infection rates, organisms, and specific factors that may alter infection risk.
Methods. Retrospective data were collected from September 2012 to 2015 for adult patients on VV ECMO. Demographic information as well as type and location of cannulation, antibiotics prior to and during cannulation, and presence of bacteremia were obtained. Counts and percentages are reported for categorical variables.
Results. 47 patients between 18 and 82 years of age with a median of age of 58 years were included. 76.6% (N = 36) were male. The average number of hospital days until cannulation was 7.8 days. 400 ECMO days were captured with a range of time on ECMO of 1-41 days. 46.8% (N = 22) of patients were alive at the time of discharge. 70.2% (N = 32) of cannulations were in the OR (Figure 1 (Figure 4 ). Due to the low number of infected patients, further statistical analysis could not be performed.
Conclusion.
We report a low rate of bloodstream infection amongst our VV-ECMO patients. Further investigation to ascertain trends in infection rate with cannulation location/type as well as association with antibiotic is currently being pursued. Other avenues of research will include a comparison of infection rates between VV and Venous Arterial (VA) ECMO. Information from these investigations will help aid the development of guidelines to minimize the rate of nosocomial infections in ECMO patients.
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Dialysis-Related Bloodstream Infections: A Pre-and Post-ClearGuard HD Cap Conception Study
William Li, MD/MPH; Caitlin Otto, PhD, D(ABMM); Mohamed Nakeshbandi, MD; Michael Augenbraun, MD; SUNY Downstate Medical University, Brooklyn, New York Session: 142. HAI, Device-Associated: Vascular Devices Friday, October 4, 2019: 12:15 PM Background. 25% of patients on hemodialysis receive therapy via a tunneled dialysis catheter (TDC). Bacteremia is one of the most feared complications with an all-cause mortality rate of 12-25%, Medicare spending costs amounting nearly $600 million annually and average hospital length of stay of 12 days per episode. The ClearGuard HD chlorhexidine impregnated catheter (ClearGuard cap) has recently shown potential to significantly reduce rates of bacteremia.
Methods. Retrospective review of 150 patients receiving hemodialysis at a single outpatient center in Brooklyn, NY from January 1, 2015 to January 31, 2019. As of February 1, 2019, the ClearGuard cap was implemented for all patients. Poisson regression was used to estimate crude event rate for both pre-and post-intervention periods, with 95% Wald-based confidence intervals (CI). Follow-up for pre-intervention cases terminated at the date the intervention was introduced. A likelihood ratio test of difference in incidence pre vs. post-intervention was conducted. A Kaplan-Meier (K-M) plot of time from the first dialysis since January 2015 to first infection was constructed (pre-intervention cases only). Subsequent subgroup analyses distinguished TDC vs. other patients. The log-rank test was used to test differences between subgroups; Bonferroni corrections to P-values were applied to address the multiple testing problem.
Results. Median total tracking period (including post-infection follow-up) was 1.75 years (range 0.02-4.26) for pre-intervention cases; 0.19 years (range 0.08-0.21) for post-intervention cases. Event rate was estimated as 9.7 events per 100 person-years (95% CI 6.7, 14.1) for pre-intervention cases; zero (95% CI 0.0, infinity) for post-intervention cases (P = 0.318 for pre-vs. post-comparison) with a clear limitation being lack of power given recent implementation date. We found a statistically significant risk for infection in patients with TDC (P < 0.001).
